Vir Biotechnology, Inc. VIR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$29K-101% | $64.07M+418% | $240K-89.9% | $1.21M-60.5% | $3.03M-94.6% | ||
| —— | —— | —— | $1.2M-60.2% | $3.03M-94.6% | ||
| $108.92M-8.2% | $88.35M-16.7% | $151.46M-22.4% | $97.51M-7.2% | $118.65M+18.5% | ||
| $23.34M-2.5% | $23.62M-11.6% | $22.23M-13.6% | $22.28M-26.4% | $23.94M-34.1% | ||
| $132.26M-7.2% | $111.99M-13.5% | $173.68M-25.7% | $119.63M-26.0% | $142.58M+4.5% | ||
| -$132.29M+5.2% | -$47.92M+59.1% | -$173.44M+25.0% | -$118.42M+25.4% | -$139.55M-74.3% | ||
| 456,172.4%+460,775pp | -74.8%+872pp | -72,267.9%-62,549pp | -9,754.3%-4,596pp | -4,602.5%-4,460pp | ||
| $6.77M-63.6% | $4.86M-61.0% | $10.47M-41.1% | $7.63M-59.3% | $18.6M+23.3% | ||
| -$125.53M-3.8% | -$43.06M+58.9% | -$162.97M+23.7% | -$110.79M+20.8% | -$120.95M-86.1% | ||
| $170K+963% | —— | $168K-5.1% | $170K+111% | $16K-94.2% | ||
| -$125.7M-3.9% | -$42.92M+59.0% | -$163.14M+23.7% | -$110.96M+19.8% | -$120.97M-85.3% | ||
| 433,431%+437,421pp | -67%+778pp | -67,975.4%-58,996pp | -9,139.9%-4,640pp | -3,989.6%-3,874pp | ||
| -$0.85+3.4% | -$0.30+60.5% | -$1.17+25.0% | -$0.80+21.6% | -$0.88-83.3% | ||
| -$129.48M+5.3% | -$45.02M+60.6% | -$170.45M+25.4% | -$115.5M+25.2% | -$136.68M-80.9% | ||
| 446,479.3%+450,987pp | -70.3%+853pp | -71,018.8%-61,422pp | -9,514%-4,494pp | -4,507.9%-4,374pp | ||
| -$132.29M+5.2% | -$47.92M+59.1% | -$173.44M+25.0% | -$118.42M+25.4% | -$139.55M-74.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Vir Biotechnology, Inc.'s revenue?
- Vir Biotechnology, Inc. (VIR) generated $65.5M in revenue over the trailing twelve months, up 214.0% year over year.
- Is Vir Biotechnology, Inc. profitable?
- Vir Biotechnology, Inc. is not currently profitable: it reported a net loss of $442.7M over the trailing twelve months, a -676.0% net margin.
- What are Vir Biotechnology, Inc.'s profit margins?
- Gross margin is 96.1% and operating margin is -720.8%, with a -676.0% net margin.
- What is Vir Biotechnology, Inc.'s earnings per share?
- Vir Biotechnology, Inc.'s diluted EPS over the trailing twelve months is $-3.12.
- Where does Vir Biotechnology, Inc.'s income statement data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
